|
|
![]() | ![]() | ![]() | ![]() |
| |||||||||
This excerpt taken from the APEI DEF 14A filed Apr 15, 2009. Certain
Relationships and Related Person Transactions
Policies
and Procedures for Related Person Transactions
Effective as of the date of our initial public offering, our
Board adopted the Code of Ethics, pursuant to which our
executive officers, directors and principal stockholders,
including their immediate family members and affiliates, are not
permitted to enter into a related person transaction with us
without the prior consent of our nominating and corporate
governance committee, or other independent committee of our
board of directors. Any request for us to enter into a
transaction with an executive officer, director, principal
stockholder or any of such persons immediate family
members or affiliates, in which the amount involved exceeds
$120,000 must first be presented to our nominating and corporate
governance committee for review, consideration and approval. All
of our directors, executive officers and employees are required
to report to our nominating and corporate governance committee
any such related person transaction. In approving or rejecting
the proposed agreement, our nominating and corporate governance
committee shall consider the facts and circumstances available
and deemed relevant to the nominating and corporate governance
committee, including, but not limited to the risks, costs and
benefits to us, the terms of the transaction, the availability
of other sources for comparable services or products, and, if
applicable, the impact on a directors independence. Our
nominating and corporate governance committee shall approve only
those agreements that, in light of known circumstances, are in,
or are not inconsistent with, our best interests, as our
nominating and corporate governance committee determines in the
good faith exercise of its discretion. Under the policy, if we
should discover related person transactions that have not been
approved, the nominating and corporate governance committee will
be notified and will determine the appropriate action, including
ratification, rescission or amendment of the transaction.
Related
Person Transactions
Set forth below is a summary of certain transactions since
January 1, 2008 among us, our directors, our executive
officers, beneficial owners of more than 5% of either our common
stock or our Class A common stock, which was outstanding
before completion of our initial public offering, and some of
the entities with which the foregoing persons are affiliated or
associated in which the amount involved exceeds or will exceed
$120,000.
In February 2008, pursuant to a public offering registered with
the SEC by us on a registration statement on
Form S-1
we sold 25,000 shares of our common stock and selling
stockholders in the offering sold additional shares of our
common stock. The selling stockholders in the offering (and the
number of shares sold) included, among others: ABS Capital
Partners IV, L.P., ABS Capital Partners IV-A, L.P., ABS Capital
Partners IV Offshore L.P. and ABS Capital Partners IV
Special Offshore L.P., which we refer to collectively as the ABS
Entities (2,500,000); Camden Partners Strategic Fund III,
L.P. and Camden Partners Strategic
Fund III-A,
L.P., which we refer to collectively as the Camden Entities
(926,460); and the following executive officers: Wallace E.
Boston, Jr. (44,000); James H. Herhusky (75,000) and Frank
B. McCluskey (25,000). Two of our directors, Philip A. Clough
and Timothy T. Weglicki, are managing members of the general
partner of the ABS Entities. One of our directors, David L.
Warnock, is a managing member of the general partner of the
Camden Entities. We did not receive any of the proceeds from the
sale of the shares of common stock by the selling stockholders
in the offering.
In December 2008, pursuant to a public offering registered with
the SEC by us on a registration statement on
Form S-3
we sold 15,000 shares of our common stock and the ABS
Entities sold 4,227,970 shares of our common stock.
In connection with the February and December 2008 offerings, we
entered into customary underwriting agreements for the offering
and incurred total costs of approximately $1.2 million.
|
| |||||||